Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on multiple discriminant analysis ((MDA)) breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 135 weeks of public selections as part of t...
Introduction Through Week 49, the Premium Portfolio has gained +27.75%, beating the S&P 500 benchmark, while actively trading in 14 fewer weeks according to the Momentum Gauge timing signals. These returns represent better than 3 times the return of the Barclay Hedge Fund Index average r...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 134 weeks of public selections as part of this ongoing live forward-testing. In...
CNS Pharmaceuticals (NASDAQ: CNSP ) initiated with Speculative Buy rating at Benchmark. More news on: CNS Pharmaceuticals, Inc., Proteostasis Therapeutics, Inc., STAAR Surgical Company, Healthcare stocks news, Stocks on the move, , Read more ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 133 weeks of public selections as part of this ongoing live forward-testing. ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 132 weeks of public selections as part of this ongoing live forward-testing. In...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 131 weeks of public selections as part of this ongoing live forward-testing. In...
STAAR Surgical Company (STAA) has a 30-year history specializing in products for eye surgery with a treatment for cataracts in 1991 and the introduction of its revolutionary "implantable collamer lenses" marketed as Visian ICL in 1996. The product here is an alternative to laser-based proced...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today that the Company will host an Investor and Analyst Day on Friday, November 8, 2019 in New York City at 8:30 a.m. EST. The eve...
Image source: The Motley Fool. Staar Surgical Co (NASDAQ: STAA) Q3 2019 Earnings Call Oct 30, 2019 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
STAAR Surgical Company Website:
2024-07-14 17:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...
2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...